[1]李　丹,张忠山,李洵婷,等.DOCK1通过AMPK/mTOR通路对多发性骨髓瘤细胞增殖、凋亡和自噬的调控机制研究[J].现代检验医学杂志,2022,37(03):62-68.[doi:10.3969/j.issn.1671-7414.2022.03.013]
　LI Dan,ZHANG Zhong-shan,LI Xun-ting,et al.Regulation Mechanism of DOCK1 on Proliferation, Apoptosis and Autophagy of Multiple Myeloma Cells Through AMPK/mTOR Pathway[J].Journal of Modern Laboratory Medicine,2022,37(03):62-68.[doi:10.3969/j.issn.1671-7414.2022.03.013]
点击复制

DOCK1通过AMPK/mTOR通路对多发性骨髓瘤细胞增殖、凋亡和自噬的调控机制研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
62-68
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Regulation Mechanism of DOCK1 on Proliferation, Apoptosis and Autophagy of Multiple Myeloma Cells Through AMPK/mTOR Pathway
文章编号:
1671-7414（2022）03-062-07
作者:
李　丹; 张忠山; 李洵婷; 曹苏娟
（湘南学院附属医院肿瘤科，湖南郴州 　423000）
Author(s):
LI Dan;  ZHANG Zhong-shan;  LI Xun-ting;  CAO Su-juan
（Department of Oncology, the Affiliated Hospital of Xiangnan College, Hunan Chenzhou 423000，China）
关键词:
多发性骨髓瘤; 胞质分裂作用因子; AMPK/mTOR 通路; 增殖; 凋亡; 自噬
分类号:
R733.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.013
文献标志码:
A
摘要:
目的　探讨胞质分裂作用因子 1（dedicator of cytokinesis 1，DOCK1）在多发性骨髓瘤（ multiple myeloma， MM）中的表达及其对癌细胞增殖、凋亡和自噬的影响及相关机制。方法　选取 MM患者骨髓组织及人 MM细胞株 U266和 RPMI 8266进行研究，采用实时荧光定量 PCR（real time-quantitative PCR，RT-qPCR）法检测 MM骨髓组织及细胞中 DOCK1相对表达；构建敲低 DOCK1表达细胞系，采用 CCK-8法和流式细胞术检测 DOCK1对 MM细胞增殖与凋亡的影响； Western blot实验检测细胞增殖相关蛋白（ c-Myc，cyclin D1）、凋亡相关蛋白（ Bax，Bcl-2）、自噬相关蛋白（ LC3-II/LC3-I，P62）及 AMPK/mTOR通路相关蛋白的表达水平。结果　LV-DOCK1-shRNA2组的 U266和 RPMI 8266细胞增殖率在 24，48和 72h均显著低于空白对照组和阴性对照组，差异均有统计学意义（ FU266=21.130～ 100.108， FRPMI8266=35.067～ 95.677，均 P<0.001）。LV-DOCK1-shRNA2组的 U266和 RPMI 8266细胞增殖相关蛋白 c-Myc， cyclin D1表达水平均显著低于阴性对照组和空白对照组（ FU266=56.061，71.584；FRPMI8266=93.248, 62.146, 均 P<0.001）。 LV-DOCK1-shRNA2组的 U266，RPMI 8266细胞 24h，48h凋亡率显著高于阴性对照组和空白对照组（ FU266=77.051， 61.533；FRPMI8266=60.868, 68.306, 均 P<0.001）。与空白对照组和阴性对照组比较， LV-DOCK1-shRNA2组 U266和 RPMI 8266细胞凋亡相关蛋白 Bax表达水平明显升高， Bcl-2表达水平明显降低（ FU266=92.588，21.940；FRPMI8266=82.736, 14.511, 均 P<0.05）；自噬相关蛋白 LC3-II/LC3-I表达水平明显升高， P62表达水平明显降低（ FU266=147.1，26.342； FRPMI8266=173.300, 31.477, 均 P<0.05）。LV-DOCK1-shRNA2组 U266，RPMI 8266细胞 AMPK/mTOR通路相关蛋白 p-AMPK表达水平明显高于阴性对照组和空白对照组（ FU266=40.542，FRPMI8266=40.892，均 P<0.05）；p-mTOR表达水平明显低于阴性对照组和空白对照组（ FU266=38.707，FRPMI8266=43.002，均 P<0.05）。在 LV-DOCK1-shRNA2组再次转染 DOCK1过表达质粒使其表达恢复后， p-AMPK和 p-mTOR表达水平也被逆转得到恢复。结论　DOCK1在多发性骨髓瘤细胞中具有促癌作用，其机制可能与通过抑制 AMPK/mTOR通路，抑制多发性骨髓瘤细胞的凋亡和自噬有关。
Abstract:
Objective　To investigate the expression of dedicator of cytokinesis 1 (DOCK1) in multiple myeloma (MM) and its effects on proliferation, apoptosis and autophagy of cancer cells and related mechanisms. Methods　Bone marrow tissue of MM patients and human MM cell line U266 and RPMI 8266 were selected for the study. Real time-quantitative PCR (RT-qPCR) was used to detect the relative expression of DOCK1 in MM bone marrow tissues and cells. Knockdown DOCK1 expression cell lines were constructed, and the effects of DOCK1 on MM cell proliferation and apoptosis were detected by CCK-8 method and flow cytometry. Western blot assay was used to detect the expression levels of proliferation-related proteins (C-MYC, cyclin D1), apoptosis-related proteins (Bax, Bcl-2), autophagy related proteins (LC3-II/LC3-I, P62) and AMPK/mTOR pathway related proteins. Results　The proliferation rates of U266 and RPMI8266 cells in LV-DOCK1-shRNA2 group were significantly lower than those in blank control group and negative control group at 24, 48 and 72h，the differences were statistically significant(FU266=21.130 ~ 100.108, FRPMI8266=35.067 ~ 95.677, all P ＜ 0.001). The expression levels of proliferation-related proteins C-myc and Cyclin D1 in LV-DOCK1-shRNA2 group were significantly lower than those in negative control group and blank control group (FU266=56.061，71.584, FRPMI8266=93.248，62.146, all P ＜ 0.001). Apoptosis rates of U266 and RPMI8266 cells in LV-DOCK1-shRNA2 group were significantly higher than those in negative control group and blank control group at 24h and 48h (FU266=77.051, 61.533, FRPMI8266=60.868，68.306, all P ＜ 0.001). Compared with blank control group and negative control group, the expression level of apoptosis-related protein Bax in U266 and RPMI 8266 cells in LV-DOCK1-shRNA2 group was significantly increased, and the expression level of Bcl-2 was significantly decreased (FU266=92.588，21.940, respectively. FRPMI8266=82.736，14.511, all P ＜ 0.05). The expression level of autophagy related protein LC3-II/LC3-I was significantly increased, and the expression level of P62 was significantly decreased (FU266=147.178，26.342, FRPMI8266=173.300，31.477, all P ＜ 0.05). The expression level of AMPK/mTOR pathway related protein p-AMPK in U266 and RPMI8266 cells in LV-DOCK1-shRNA2 group was significantly higher than that in negative control group and blank control group (FU266=40.542，FRPMI8266=40.892, all P ＜ 0.05). The expression level of p-mTOR was significantly lower than that of negative control group and blank control group (FU266=38.707，FRPMI8266=43.002, all P ＜ 0.05). In the LV-DOCK1-shrNA2 group, the expression of DOCK1-overexpressed plasmid was recovered by transfection, and the expression levels of P-AMPK and P-MTOR were also reversed and recovered. Conclusion　DOCK1 has a carcinogenic effect in multiple myeloma cells, and the mechanism may be related to inhibiting apoptosis and autophagy of multiple myeloma cells by inhibiting AMPK/mTOR pathway.

参考文献/References:

[1] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性多发性骨髓瘤专业委员 会. 中国多发性多发性骨髓瘤诊治指南(2020 年修 订)[J]. 中华内科杂志, 2020, 59(5):341-346. Chinese Hematology Association, Chinese Society of Hematology, Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)[J]. Chinese Journal of Internal Medicine, 2020, 59(5):341-346.
[2] 徐海燕, 陆学东．多发性骨髓瘤早期实验诊断相关 新兴生物标志物的最新研究进展[J]. 现代检验医学 杂志, 2021, 36(5):180-183. XU Haiyan, LU Xuedong. Recent research progress of novel biomarkers for early experimental diagnosis of multiple myeloma [J]. Journal of Modern Laboratory Medicine, 2021,36(5):180-183.
[3] LIANG Yueyang, WANG Shushu, ZHANG Yi. Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway [J]. Oncology Letters, 2018, 16(3): 3481-3488.
[4] SUN Xujuan, LIU Shuqing, WANG Jinxia, et al. Annexin A5 regulates hepatocarcinoma malignancy via CRKI/II-DOCK180-RAC1 integrin and MEK-ERK pathways[J]. Cell Death & Disease, 2018, 9(6): 637.
[5] FERRARI M G, GANAIE A A, SHABENAH A, et al. Identifying and treating ROBO1-ve /DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients[J]. The Prostate, 2020, 80(13): 1045-1057.
[6] ZHANG Gaoqi, ZHANG Jilei, YANG Xinrui, et al. High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Cancer Management and Research, 2019, 11: 3053-3060.
[7] PAN Yan, LI Xin, DUAN Jianhui, et al. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation[J]. Molecular Pharmacology, 2015, 87(3): 378-390.
[8] 王振, 胡峻铮, 范卫民．脂联素通过AMPK/mTOR 通路抑制H2O2 诱导的大鼠髓核细胞凋亡及细胞外 基质退变[J]. 南京医科大学学报（自然科学版）, 2018, 38(7):928-933, 961. WANG Zhen, HU Junzheng, FAN Weimin. Adiponectin inhibits H2O2-induced apoptosis and extracellular matrix degradation in rat nucleus pulposus cells through AMPK/mTOR pathway [J]. Journal of Nanjing Medicial University (Natural Sciences),2018,38(7):928-933, 961.
[9] MEI Huiling, XIANG Yu, MEI Heng, et a l . Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells[J]. International Journal of Molecular Medicine, 2018, 42(5): 2676-2688.
[10] 蒙星烨, 肖晶莹, 谭哲伦, 等. 细胞质分裂付出蛋 白1 在肿瘤发生发展中的作用[J]. 生理科学进展, 2019, 50(5):343-347. MENG Xingye, XIAO Jingying, TAN Zhelun, et al. The role of cytokinesis donor protein 1 in tumorigenesis and development[J]. Progress in Physiological Sciences, 2019,50(5):343-347.
[11] TOMINO T, TAJIRI H, TATSUGUCHI T, et al. DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1(P29S) mutation[J]. Biochemical and Biophysical Research Communications, 2018, 497(1): 298-304.
[12] LI Wenjing, XIONG Xiahui, ABDALLA A, et al. HGF-induced formation of the MET-AXL-ELMO2- DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion[J]. The Journal of Biological Chemistry, 2018, 293(40): 15397-15418.
[13] YANG Xiaoyu, WANG Yan, PANG Sulei, et al. LINC00665 promotes the progression of acute myeloid leukemia by regulating the miR-4458/DOCK1 pathway[J]. Scientific Reports, 2021, 11(1): 5009.
[14] 田向东, 夏雨人, 周德俊, 等. 自噬在肿瘤细胞休眠 中作用及相关机制研究进展[J]. 中国实用外科杂志, 2022, 42(3):331-336. TIAN Xiangdong, XIA Yuren, ZHOU Dejun, et al. Role of autophagy in tumor cell dormancy and underlying mechanism [J]. Chin J Practical Surgery, 202, 42(3):331-336.
[15] MOWERS E E, SHARIFI M N, MACLEOD K F. Functions of autophagy in the tumor microenvironment and cancer metastasis[J]. The FEBS Journal, 2018, 285(10): 1751-1766.
[16] SUI Tianqi, WANG Xiaoyang, LI Lili, et al. GOLM1 suppresses autophagy-mediated anti-tumor immunity in hepatocellular carcinoma[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 335.
[17] 魏砚明, 任晋宏, 栾智华, 等．多种细胞自噬调节剂 对自噬标记物LC3 Ⅱ及p62 表达的影响[J]. 中国药 科大学学报, 2018, 49(3):341-347. WEI Yanming, REN Jinhong, LUAN Zhihua, et al. Effects of various autophagy modulators on the expression of autophagic markers LC3 Ⅱ and p62 [J]. Journal of China Pharmaceutical University, 2018, 49(3):341-347.
[18] 李志元, 张欣．细胞自噬研究方法的比较与分析[J]. 生物学杂志, 2018, 35(4):1-6. LI Zhiyuan, ZHANG Xin. Comparison and analysis of methods in autophagy research [J]. Journal of Biology,2018,35(4):1-6.
[19] WANG Yan, XU Wenbin, YAN Zixun, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 63.
[20] XIAO Feng, OUYANG Binshen, ZOU Jue, et al. Trim14 promotes autophagy and chemotherapy resistance of gastric cancer cells by regulating AMPK/ mTOR pathway[J]. Drug Development Research, 2020, 81(5): 544-550.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(03):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(03):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(03):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(03):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(03):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(03):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(03):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(03):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

备注/Memo

备注/Memo:
基金项目：湖南省科技计划一般项目（2019SK3151）。
作者简介：李丹（1987-），女，硕士研究生，主治医师，研究方向：血液肿瘤方向，E-mail：xueqing37@163.com。
通讯作者：曹苏娟（1978-），女，本科，硕士，主任医师，研究方向：肿瘤化疗。
更新日期/Last Update: 1900-01-01